Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pulmonary Medicine
Published in: BMC Pulmonary Medicine 1/2015

Open Access 01-12-2015 | Research article

Dynamics of IL-4 and IL-13 expression in the airways of sheep following allergen challenge

Authors: Bahar Liravi, David Piedrafita, Gary Nguyen, Robert J. Bischof

Published in: BMC Pulmonary Medicine | Issue 1/2015

Login to get access

Abstract

Background

IL-4 and IL-13 play a critical yet poorly understood role in orchestrating the recruitment and activation of effector cells of the asthmatic response and driving the pathophysiology of allergic asthma. The house dust mite (HDM) sheep asthma model displays many features of the human condition and is an ideal model to further elucidate the involvement of these critical Th2 cytokines. We hypothesized that airway exposure to HDM allergen would induce or elevate the expression profile of IL-4 and IL-13 during the allergic airway response in this large animal model of asthma.

Methods

Bronchoalveolar lavage (BAL) samples were collected from saline- and house dust mite (HDM)- challenged lung lobes of sensitized sheep from 0 to 48 h post-challenge. BAL cytokines (IL-4, IL-13, IL-6, IL-10, TNF-α) were each measured by ELISA. IL-4 and IL-13 expression was assessed in BAL leukocytes by flow cytometry and in airway tissue sections by immunohistology.

Results

IL-4 and IL-13 were increased in BAL samples following airway allergen challenge. HDM challenge resulted in a significant increase in BAL IL-4 levels at 4 h compared to saline-challenged airways, while BAL IL-13 levels were elevated at all time-points after allergen challenge. IL-6 levels were maintained following HDM challenge but declined after saline challenge, while HDM administration resulted in an acute elevation in IL-10 at 4 h but no change in TNF-α levels over time. Lymphocytes were the main early source of IL-4, with IL-4 release by alveolar macrophages (AMs) prominent from 24 h post-allergen challenge. IL-13 producing AMs were increased at 4 and 24 h following HDM compared to saline challenge, and tissue staining provided evidence of IL-13 expression in airway epithelium as well as immune cells in airway tissue.

Conclusion

In a sheep model of allergic asthma, airway inflammation is accompanied by the temporal release of key cytokines following allergen exposure that primarily reflects the Th2-driven nature of the immune response in asthma. The present study demonstrates for the first time the involvement of IL-4 and IL-13 in a relevant large animal model of allergic airways disease.
Literature
1.
2.
3.
Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183–92.CrossRefPubMed
4.
5.
6.
7.
Finkelman FD, Boyce JA, Vercelli D & Rothenberg ME. Key advances in mechanisms of asthma, allergy, and immunology in 2009. J Allergy Clin Immunol. 2010;125(2):312–8.
8.
Daher S, Santos LM, Sole D, De Lima MG, Naspitz CK & Musatti CC. Interleukin-4 and soluble CD23 serum levels in asthmatic atopic children. J Investig Allergol Clin Immunol. 1995;5(5):251–4.
9.
Walker C, Kaegi MK, Braun P & Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol. 1991;88(6):935–42.
10.
Shi H, Qin S, Huang G, Chen Y, Xiao C, Xu, H  et al. Infiltration of eosinophils into the asthmatic airways caused by interleukin 5. Am J Respir Cell Mol Biol. 1997;16(3):220–4.
11.
Herrick CA, Bottomly K. To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol. 2003;3(5):405–12.CrossRefPubMed
12.
13.
Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol. 1997;99(5):657–65.
14.
Kroegel C, Julius P, Matthys H, Virchow JcJ, Luttmann W. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J. 1996;9(5):899–904.
15.
Prieto J, Lensmar C, Roquet A, van der Ploeg I, Gigliotti D, Eklund A & Grunewald J. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir Med. 2000;94(8):806–14.
16.
Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282(5397):2261–3.
17.
Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL & Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258–61.
18.
Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I & Rothenberg ME. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005;35(8):1096–103.
19.
De Boever EH, Ashman C, Cahn AP, Locantore NW, Overend P, Pouliquen IJ et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133(4):989–96.
20.
Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–8.
21.
Collie DD. Comparative, complementary and relevant: the immunological basis of ovine lung allergic responses. Clin Exp Allergy. 2003;33(3):282–6.CrossRefPubMed
22.
Meeusen EN, Snibson KJ, Hirst SJ, Bischof RJ. Sheep as a model species for the study and treatment of human asthma and other respiratory diseases. Drug Discov Today Dis Models. 2010;6(4):101–6.
23.
Bischof RJ, Snibson K, Shaw R, Meeusen EN. Induction of allergic inflammation in the lungs of sensitized sheep after local challenge with house dust mite. Clin Exp Allergy. 2003;33(3):367–75.
24.
Snibson KJ, Bischof RJ, Slocombe RF, Meeusen EN. Airway remodelling and inflammation in sheep lungs after chronic airway challenge with house dust mite. Clin Exp Allergy. 2005;35(2):146–52.
25.
Kirschvink N, Reinhold P. Use of alternative animals as asthma models. Curr Drug Targets. 2008;9(6):470–84.CrossRefPubMed
26.
Allen JE, Bischof RJ, Sucie Chang HY, Hirota JA, Hirst SJ, Inman MD et al. Animal models of airway inflammation and airway smooth muscle remodelling in asthma. Pulm Pharmacol Ther. 2009;22(5):455–65.
27.
Miller LA, Hurst SD, Coffman RL, Tyler NK, Stovall MY, Chou DL et al. Airway generation-specific differences in the spatial distribution of immune cells and cytokines in allergen-challenged rhesus monkeys. Clin Exp Allergy. 2005;35(7):894–906.
28.
Bischof RJ, Snibson KJ, Van Der Velden J, Meeusen EN. Immune response to allergens in sheep sensitized to house dust mite. J Inflamm (Lond). 2008;5:16.
29.
Hope JC, Kwong LS, Entrican G, Wattegedera S, Vordermeier HM, Sopp P & Howard CJ. Development of detection methods for ruminant interleukin (IL)-12. J Immunol Methods. 2002;266(1–2):117–26.
30.
Kwong LS, Hope JC, Thom ML, Sopp P, Duggan S, Bembridge GP & Howard CJ. Development of an ELISA for bovine IL-10. Vet Immunol Immunopathol. 2002;85(3–4):213–23.
31.
Abeynaike L, Meeusen ENT, Bischof RJ. An ovine tracheal explant culture model for allergic airway inflammation. J Inflamm (Lond). 2010;7:46–55.CrossRef
32.
Bischof RJ, Meeusen EN. Cellular kinetics of an allergic-type response in a sheep mammary gland model of inflammation. Clin Exp Allergy. 2002;32(4):619–26.CrossRefPubMed
33.
Gallelli L, Busceti MT, Vatrella A, Maselli R & Pelaia G. Update on anticytokine treatment for asthma. Biomed Res Int. 2013;2013:104315.
34.
35.
Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2):299–310. quiz 311.CrossRefPubMed
36.
Walsh G.M. Anti-IL-4/-13 based therapy in asthma. Expert Opin Emerg Drugs. 2015;20(3):349-52.
37.
Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol. 2012;130(4):829–42. quiz 843–4.CrossRefPubMed
38.
Abbas AR, Jackman JK, Bullens SL, Davis SM, Choy DF, Fedorowicz G et al. Lung gene expression in a rhesus allergic asthma model correlates with physiologic parameters of disease and exhibits common and distinct pathways with human asthma and a mouse asthma model. Am J Pathol. 2011;179(4):1667–80.
39.
40.
Dewachi O, Joubert P, Hamid Q & Lavoie JP. Expression of interleukin (IL)-5 and IL-9 receptors on neutrophils of horses with heaves. Vet Immunol Immunopathol. 2006;109(1–2):31–6.
41.
Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2(2):66–70.CrossRefPubMedPubMedCentral
42.
Collie DD, McLean N, Sallenave JM, Baker A, Blundell R, Milne E et al. Local lung responses following endobronchial elastase and lipopolysaccharide instillation in sheep. Int J Chron Obstruct Pulmon Dis. 2006;1(2):189–99.
43.
Collie DD, Baker A, Mauchline S, Porteous D & Mc Lachlan G. Ovine bronchoalveolar lavage cellularity: reproducibility and the effect of multiple repeated lavage. Res Vet Sci. 1999;67(2):137–40.
44.
Temann UA, Geba GP, Rankin JA & Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med. 1998;188(7):1307–20.
45.
Moreira AP, Hogaboam CM. Macrophages in allergic asthma: fine-tuning their pro- and anti-inflammatory actions for disease resolution. J Interferon Cytokine Res. 2011;31(6):485–91.CrossRefPubMed
46.
Loke P, Nair MG, Parkinson J, Guiliano D, Blaxter M & Allen JE. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol. 2002;3:7.
47.
Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol. 2007;179(8):5367–77.
48.
Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96.CrossRefPubMed
49.
Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. 2013;31:317–43.CrossRefPubMedPubMedCentral
50.
Melgert BN, ten Hacken NH, Rutgers B, Timens W, Postma DS & Hylkema MN. More alternative activation of macrophages in lungs of asthmatic patients. J Allergy Clin Immunol. 2011;127(3):831–3.
51.
Yang M, Kumar RK, Hansbro PM & Foster PS. Emerging roles of pulmonary macrophages in driving the development of severe asthma. J Leukoc Biol. 2012;91(4):557–69.
52.
Kang CM, Jang AS, Ahn MH, Shin JA, Kim JH, Choi YS et al. Interleukin-25 and interleukin-13 production by alveolar macrophages in response to particles. Am J Respir Cell Mol Biol. 2005;33(3):290–6.
53.
La Flamme AC, Kharkrang M, Stone S, Mirmoeini S, Chuluundorj D & Kyle R. Type II-activated murine macrophages produce IL-4. PLoS One. 2012;7(10), e46989.
54.
Balhara J, Gounni AS. The alveolar macrophages in asthma: a double-edged sword. Mucosal Immunol. 2012;5(6):605–9.CrossRefPubMed
55.
Hancock A, Armstrong L, Gama R & Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol. 1998;18(1):60–5.
56.
Varin A, Mukhopadhyay S, Herbein G & Gordon S. Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion. Blood. 2010;115(2):353–62.
57.
Ullah MA, Revez JA, Loh Z, Simpson J, Zhang V, Bain L et al. Allergen-induced IL-6 trans-signaling activates gammadelta T cells to promote type 2 and type 17 airway inflammation. J Allergy Clin Immunol. 2015. doi:10.​1016/​j.​jaci.​2015.​02.​032.
58.
Colavita AM, Hastie AT, Musani AI, Pascual RM, Reinach AJ, Lustine HT et al. Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects. J Allergy Clin Immunol. 2000;106(5):880–6.
59.
60.
61.
Yang Z, Grinchuk V, Urban JF Jr, Bohl J, Sun R, Notari L et al. Macrophages as IL-25/IL-33-responsive cells play an important role in the induction of type 2 immunity. PLoS One. 2013;8(3), e59441.
62.
Willis CR, Siegel L, Leith A, Mohn D, Escobar S, Wannberg S et al. IL-17RA signaling drives airway inflammation and bronchial hyper reactivity in allergic asthma. Am J Respir Cell Mol Biol. 2015. doi:10.​1165/​rcmb.​2015-0038OC.
63.
Hallstrand TS, Hackett TL, Altemeier WA, Matute-Bello G, Hansbro PM & Knight DA. Airway epithelial regulation of pulmonary immune homeostasis and inflammation. Clin Immunol. 2014;151(1):1–15.
64.
Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol. 2009;182(8):4994–5002.CrossRefPubMedPubMedCentral
65.
Collison A, Herbert C, Siegle JS, Mattes J, Foster PS & Kumar RK. Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment. J Allergy Clin Immunol. 2011;128(1):160–7. e4.
66.
Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316(5824):608–11.
67.
Malmhall C, Alawieh S, Lu Y, Sjostrand M, Bossios A, Eldh M & Radinger M. MicroRNA-155 is essential for T(H)2-mediated allergen-induced eosinophilic inflammation in the lung. J Allergy Clin Immunol. 2014;133(5):1429–38. 1438 e1-7.
Metadata
Title
Dynamics of IL-4 and IL-13 expression in the airways of sheep following allergen challenge
Authors
Bahar Liravi
David Piedrafita
Gary Nguyen
Robert J. Bischof
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2015
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-015-0097-9

Other articles of this Issue 1/2015

BMC Pulmonary Medicine 1/2015 Go to the issue

Technical advance

Identification of new biomarkers for Acute Respiratory Distress Syndrome by expression-based genome-wide association study

Research article

Association between pulmonologists’ tobacco use and their effort in promoting smoking cessation in Turkey: a cross-sectional study

Research article

Role of sedation for agitated patients undergoing noninvasive ventilation: clinical practice in a tertiary referral hospital

Research article

Immune response to Propionibacterium acnes in patients with sarcoidosis – in vivo and in vitro

Research article

Adherence to treatment in children and adolescents with cystic fibrosis: a cross-sectional, multi-method study investigating the influence of beliefs about treatment and parental depressive symptoms

Research article

A comparison of visual and quantitative methods to identify interstitial lung abnormalities
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits